LABETALOL HYDROCHLORIDE

Post-LOE

labetalol hydrochloride

Hikma

ANDAORALTABLET

Approved

Sep 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LABETALOL HYDROCHLORIDE (labetalol hydrochloride) by Hikma is selective, competitive, alpha1‑adrenergic blocking and nonselective, competitive, beta‑adrenergic blocking activity. Approved for hypertension, to lower blood pressure. First approved in 2025.

Drug data last refreshed 18h ago

Mechanism of Action

selective, competitive, alpha1‑adrenergic blocking and nonselective, competitive, beta‑adrenergic blocking activity. The ratios of alpha- to beta‑blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively.

Indications (2)

hypertension to lower blood pressure

Worked on LABETALOL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.